At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 47 enrolled
Drug / intervention
CP-751,871drug
Likely dose
CP-751,871 0.025 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase I Study Of CP-751,871 In Patients With Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating CP-751,871 for Multiple Myeloma. Completed, enrolled 47 participants across 6 sites.
Detailed Summary
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2003
Primary CompletionJun 2008
First PostedFeb 2012
TodayJul 2026
First PostedFeb 20, 2012
Enrollment StartDec 1, 2003
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 14.4 years ago
Interventions
CP-751,871drug
CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability